Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The chronic and acute postprandial vascular effects of exenatide vs. metformin in abdominally obese patients with impaired glucose tolerance.

Next Previous
Trial Profile

The chronic and acute postprandial vascular effects of exenatide vs. metformin in abdominally obese patients with impaired glucose tolerance.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Nov 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Exenatide (Primary) ; Metformin
  • Indications Glucose intolerance; Obesity
  • Focus Biomarker; Pharmacodynamics

Most Recent Events

  • 12 Jun 2012 Primary endpoint 'Endothelial-function' has not been met according to results presented at the 72nd Annual Scientific Sessions of the American Diabetes Association.
  • 12 Jun 2012 Results presented at the 72nd Annual Scientific Sessions of the American Diabetes Association.
  • 17 Aug 2011 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top